Clinical Trials Browser

INDUSTRY × Recurrence × talquetamab × Clear all

NCT03601078 2026-03-04

KarMMa-2

Phase 2 Completed

Multiple Myeloma, Recurrence

NCT05455320 2026-01-16

MonumenTAL-3

Phase 3 Active not recruiting

Multiple Myeloma, Recurrence

NCT05757973 2025-12-09

Pre-Approval Access Program for Talquetamab in Relapsed or Refractory Multiple Myeloma

Approved for marketing

Multiple Myeloma, Recurrence